REG - CRISM Therapeutics - Phase 2 Clinical Trial Progress Update

CRISM TherapeuticsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260325:nRSY9592Xa&default-theme=true

RNS Number : 9592X  CRISM Therapeutics Corporation  25 March 2026

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No.
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act
2018. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

 

 

25 March 2026

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Phase 2 Clinical Trial Progress Update

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery
company focused on the localised and sustained delivery of chemotherapy drugs,
provides a progress update on its Phase 2 clinical trial of
irinotecan-ChemoSeed in glioblastoma.

The Company confirms that its US-based contract development and manufacturing
organisation, ProMed Pharma LLC, has successfully manufactured the first
clinical batch of ChemoSeed in accordance with current Good Manufacturing
Practice standards. The batch will now undergo sterilisation and release
testing, making it ready for use in the Phase 2 trial.

The Company also continues to work closely with its contract research
organisation, Aixial, and the first clinical trial site, to complete the
remaining site activation steps so as to commence patient dosing. Although
progress toward trial commencement is moving at pace, the exact timing of
first patient dosing is difficult to anticipate. As such, the Company is
extending guidance on the timing of first patient dosing to H1 2026.  The
Company remains focused on initiating the trial shortly and will provide
further updates on the commencement of the trial as soon as possible.

 

 

-Ends-

 

 

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, Chairman           Richard Morrison                  Henry Harrison Topham / Jamie Hooper

 Chris McConville, CSO           Vadim Alexandre                   CRISM@buchanancomms.co.uk

                                 Adam Cowl
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

The Company's LEI is 213800XFW6MKVCHHPW88.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDZGZFVDZGVZM



            Copyright 2019 Regulatory News Service, all rights reserved